A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma Correspondence

  


Authors: Gurumurthi, A.; Bantilan, K. S.; Hamlin, P. A.; Kumar, A.; Matasar, M.; Zhu, M.; Joseph, A.; Castro, A.; Biggar, E.; Salles, G.; Zelenetz, A. D.; von Keudell, G.
Title: A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma
Keywords: adult; clinical article; controlled study; aged; prednisone; constipation; fatigue; cancer recurrence; doxorubicin; cancer combination chemotherapy; diarrhea; drug efficacy; drug safety; side effect; rituximab; cancer staging; letter; anorexia; ki 67 antigen; mantle cell lymphoma; multiple cycle treatment; neutrophil count; anemia; tumor volume; nausea; randomized controlled trial; thrombocytopenia; cohort analysis; creatinine; cyclophosphamide; vincristine; autologous stem cell transplantation; creatinine blood level; protein p53; abdominal pain; backache; drug dose escalation; fever; hyponatremia; maculopapular rash; peripheral edema; limb pain; sepsis; maximum tolerated dose; phase 1 clinical trial; leukocytosis; atrial fibrillation; adverse drug reaction; upper respiratory tract infection; second-line treatment; overall response rate; diffuse large b cell lymphoma; contusion; immunoglobulin heavy chain gene; Common Terminology Criteria for Adverse Events; abexinostat; ibrutinib; human; chimeric antigen receptor t-cell immunotherapy; line of treatment; non germinal center diffuse large b cell lymphoma
Journal Title: Leukemia and Lymphoma
Volume: 65
Issue: 14
ISSN: 1042-8194
Publisher: Taylor & Francis Group  
Date Published: 2024-01-01
Start Page: 2224
End Page: 2227
Language: English
DOI: 10.1080/10428194.2024.2398658
PUBMED: 39303057
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85204550588&doi=10.1080%2f10428194.2024.2398658&partnerID=40&md5=540ecdfa72f2401345238a22c9aa8b61
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF. Corresponding MSK author is Andrew d. Zelenetz -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Andrew D Zelenetz
    767 Zelenetz
  2. Paul Hamlin
    276 Hamlin
  3. Matthew J Matasar
    289 Matasar
  4. Anita Kumar
    180 Kumar
  5. Kurt Bantilan
    25 Bantilan
  6. Gottfried Von Keudell
    54 Von Keudell
  7. Erin Biggar
    6 Biggar
  8. Menglei Zhu
    35 Zhu
  9. Gilles Andre Salles
    269 Salles
  10. Ashlee Joseph
    16 Joseph
  11. Ashwath Gurumurthi
    5 Gurumurthi
  12. Ali Castro
    1 Castro
Related MSK Work